Wharton’s Jelly as an MSC Source: Why Tissue Origin Determines Secretome and Vesicle Cargo

The Word on the Label Is Doing More Work Than It Looks

Aross the regenerative supply chain, tissue source appears in marketing copy as a quality signal. Umbilical cord derived reads as premium, adipose reads as convenient, bone marrow reads as established. The vocabulary is doing the work of a specification while carrying none of the precision a specification requires, and a practitioner who buys on that vocabulary has bought a category rather than a material.

The literature supports a narrower and more useful claim. Mesenchymal stromal cells isolated from different tissues express different transcriptional programs, secrete different protein profiles, and load their extracellular vesicles with different cargo. Those differences are reproducible enough that a comparative proteomic study can distinguish four sources by signature alone.^[4] They are also large enough that substituting one source for another produces a different product rather than a different grade of the same one.

What follows is a source-level review of Wharton’s jelly organized around the questions a practitioner actually has to answer at the point of purchase. Where does the material come from anatomically, what is measurably distinct about it, what does the clinical literature currently support, and what documentation should accompany it. The intent is to make the sourcing conversation specific enough that a supplier either answers it or reveals that they cannot.

What Wharton's Jelly Actually Is

Wharton’s jelly is the mucous connective tissue that fills the umbilical cord and surrounds its two arteries and single vein. It is a hydrated matrix dominated by hyaluronic acid and sulfated glycosaminoglycans, embedded with a sparse population of fibroblast-like stromal cells, and it carries no lymphatic drainage and no vasculature of its own. Its physiological job is mechanical, which is to resist compression and torsion so that cord blood flow survives fetal movement.

Two features of that description matter commercially. The first is that the tissue is discarded at delivery, which removes the invasive harvest step that constrains bone marrow and adipose sourcing and removes the donor-age problem along with it. The second is that the cord is not homogeneous. Isolation protocols draw from anatomically distinct zones, and cells recovered from those zones differ in marker expression and behavior.^[5]

The fourth entry above is the one worth pressing on. A supplier who describes their starting material only as umbilical cord has told a purchaser which organ was used and nothing about which tissue within it. Two products bearing that identical description can originate from different zones, follow different dissection protocols, and produce isolates that a marker panel would separate. Asking which zone, and asking whether the answer is documented in a batch record, is a fast way to establish whether a supplier controls their process or merely sources it.

The Immunophenotype Behind the Allogeneic Argument

The allogeneic case for perinatal tissue rests on a specific expression pattern rather than on a general appeal to youth. Cells from this tissue express low to moderate MHC class I, lack MHC class II including HLA-DR, and lack the costimulatory molecules CD40, CD80 and CD86 required to prime a naive T-cell response.^[1] They additionally secrete immune inhibitory mediators including prostaglandin E2, indoleamine 2,3-dioxygenase and HLA-G, and they expand regulatory T-cell populations in co-culture.^[1][6]

That combination is why the tissue is studied in allogeneic settings, and it is also where honest comparison becomes necessary. In head-to-head suppression assays, bone marrow derived cells have been reported as the most effective T-cell suppressors under some conditions, while cord and adipose derived populations suppress lymphocyte responses through a partly different route involving leukemia inhibitory factor secretion.^[2] The accurate statement is that the sources use different immunological machinery, and a claim that one source is simply more immunomodulatory than another usually reflects which assay was chosen rather than a settled result.

Transcriptome-level comparison sharpens the point. Cells from this tissue display a distinct immunomodulatory and proregenerative expression signature relative to bone marrow rather than an amplified version of the same signature.^[2] For a practitioner, the operational translation is that source substitution is a formulation change and should be treated with the same seriousness as changing an active ingredient.

Where the Sources Measurably Diverge

The most decision-relevant comparison in this literature profiled the secretome of cells from adipose tissue, bone marrow, placenta and Wharton’s jelly under matched conditions.^[4] Two findings emerged together, and quoting only one of them is how most marketing copy goes wrong.

Biophysics Is the Part Most COAs Skip

Biological characterization tells a purchaser what the material might do. Biophysical characterization tells them what is actually in the vial, and it is the part that separates a controlled product from a preparation.

Published biophysical work on vesicles from this tissue reports size distribution, zeta potential and morphology as primary descriptors.^[7] More recent work separates large from small vesicle populations and demonstrates that the two fractions differ in immunomodulatory behavior.^[8] That result has a direct consequence for how particle counts should be read. A single total-particle figure with no size distribution behind it aggregates two populations that the literature has shown behave differently, which makes the number difficult to interpret and easy to inflate.

The reporting framework the field settled on is MISEV2023, which specifies what should be measured and disclosed for vesicle preparations across production, separation and characterization.^[12][22] A supplier characterization package that maps cleanly onto MISEV categories was assembled by people who read the guidance. One that does not was assembled by people who did not, and that inference is usually reliable. Our companion piece on evaluating an exosome supplier COA works through the individual line items in detail.

Scale introduces a separate question. Isolation methods that behave predictably at bench scale do not automatically transfer to clinical-scale production, and consistency across batches is a manufacturing property rather than a biological one.^[11] Asking a supplier how many batches they have released, and whether release specifications have ever failed, gets closer to the truth than asking what their product contains.

Source Comparison Table

Comparative characteristics drawn from references 1 through 6. The table summarizes reported tendencies across studies rather than establishing ranking, and assay conditions differ enough between publications that direct numerical comparison across rows is not supportable.

What the Human Literature Currently Supports

Two categories of human evidence exist for this tissue source, and they sit at very different levels of rigor.

The first is registered investigational work. A phase I study evaluated two doses of Wharton’s jelly derived stromal cells in de novo high-risk or steroid-refractory acute graft versus host disease.^[13] That trial matters less for its endpoint than for its structure, since it demonstrates what this material looks like when it moves through an IND pathway with defined manufacturing, defined dosing and defined safety monitoring.

The second is the musculoskeletal literature, which is larger and considerably softer. A systematic review of umbilical cord and Wharton’s jelly derived cell treatment in knee osteoarthritis and chondral injury reported functional improvement across VAS, WOMAC, KOOS and IKDC measures with mixed radiological findings and no severe adverse effects.^[14] The divergence between symptom scores and imaging is the honest summary. A protocol for a randomized, controlled, single-blind multi-center comparison against hyaluronic acid and saline has been published, which is the comparison the observational literature has been missing.^[15]

For a practitioner writing patient-facing material, the safe formulation follows the structure of the evidence. Published work reports functional improvement in uncontrolled and partly controlled settings, controlled comparison against standard injectables is still in progress, and no product in this category has FDA approval for the treatment of any disease.

Which Framework the Product Sits Inside

Birth-tissue products occupy one of two regulatory positions, and the distinction is not a matter of supplier preference.

A product regulated solely under Section 361 must satisfy every criterion at 21 CFR 1271.10(a), including minimal manipulation and homologous use.^[19] FDA guidance addresses these criteria directly and includes umbilical tissue in its worked reasoning.^[16] A product failing any criterion is regulated as a drug or biologic and requires an IND to be studied and a BLA to be marketed. Donor eligibility, screening and testing obligations sit at Subpart C, and current good tissue practice sits at Subpart D, and a supplier should be able to say which subparts they operate under without consulting anyone.^[19]

Cell-free vesicle preparations sit in a distinct position again. FDA has stated that there are no approved exosome products and issued a public safety notification after serious adverse events in patients treated with unapproved preparations, followed by a consumer-facing alert.^[17][18] Enforcement in this category is active and searchable, and running a prospective supplier through the warning letter database is the cheapest diligence available.^[24] Florida practices carry an additional state-level disclosure obligation under SB 1768.^[23] Our standing summary of the federal position is maintained at is exosome therapy FDA-approved, and the Florida-specific analysis sits in stem cell sourcing for Florida clinics.

Release documentation should name compendial methods rather than assert outcomes. Sterility against USP General Chapter 71 and bacterial endotoxin against General Chapter 85, each reported with the method and the limit, is the minimum a practitioner should expect on paper.^[20][21]

Eight Questions That Separate Suppliers

The following questions are answerable in a single email by a supplier who controls their process. Slow or partial answers are themselves data.

Which anatomical zone. Perivascular, intervascular, subamniotic, or whole-cord homogenate, and is the answer recorded in the batch record.

Donor screening and testing. Which 21 CFR 1271 Subpart C requirements were applied, and who determined donor eligibility.

Passage number at harvest. Expansion history changes expression profile, and a source advantage evaporates if the material was expanded past it.

Size distribution across the full particle range. Large and small vesicle fractions behave differently, so a single aggregate number under-describes the product.

Characterization mapped to MISEV2023. Which markers, which methods, and which negative controls were run.

Compendial release testing. Sterility and endotoxin reported by method and limit rather than as a pass mark.

Batch history. How many batches released, and whether any batch has failed a release specification.

Regulatory posture. Whether the product is offered as a 361 HCT/P, under an IND, or for research and topical aesthetic use only, stated in writing.

Closing Observation

The comparative literature supports a real and specific claim about this tissue. Perinatal origin fixes donor age at birth, the immunophenotype lacks the class II and costimulatory machinery required to prime an allogeneic response, and the secretome carries a signature distinguishable from adipose, bone marrow and placenta under matched conditions. Those are measurable properties with citations behind them.

What the literature does not support is the inferential leap most marketing makes next, which is that a distinctive secretome guarantees a superior clinical result. The same comparative study that separates the sources also shows they share their most commonly advertised functions, and the human evidence in aesthetics and orthopedics remains thinner than the mechanistic evidence by a wide margin. Practitioners who hold both facts at once will source better, will describe their offerings more accurately, and will be considerably harder to sell a vial to on the strength of a word on a label.

Annotated References

Twenty-four sources, each annotated with why it is cited and what it does or does not establish. Fifteen are peer-reviewed journal articles; the remainder are federal regulations, agency guidance, and compendial standards.

1. 1.Peer-reviewedWeiss ML, Anderson C, Medicetty S, et al. Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells. 2008;26(11):2865-2874. https://pubmed.ncbi.nlm.nih.gov/18703664/The foundational immunophenotyping paper for this tissue. Establishes the low class I, absent class II, absent costimulatory molecule pattern that underlies every subsequent allogeneic argument. Read this before accepting any supplier claim of immune privilege.
2. 2.Peer-reviewedDonders R, Bogie JFJ, Ravanidis S, et al. Human Wharton's jelly-derived stem cells display a distinct immunomodulatory and proregenerative transcriptional signature compared to bone marrow-derived stem cells. Stem Cells and Development. 2018;27(2):65-84. https://pubmed.ncbi.nlm.nih.gov/29267140/Transcriptome-level comparison against bone marrow. The relevant finding for sourcing is that the difference is a distinct expression program rather than a quantitative shift, which is why source substitution changes the product rather than the potency.
3. 3.Peer-reviewedBalasubramanian S, Thej C, Venugopal P, et al. Higher propensity of Wharton's jelly derived mesenchymal stromal cells towards neuronal lineage in comparison to those derived from adipose and bone marrow. Cell Biology International. 2013;37(5):507-515. https://pubmed.ncbi.nlm.nih.gov/23418097/Three-way differentiation comparison. Useful mainly as evidence that lineage bias tracks with tissue of origin, a point that generalizes past the neuronal endpoint the authors chose.
4. 4.Peer-reviewedShin S, Lee J, Kwon Y, et al. Comparative proteomic analysis of the mesenchymal stem cells secretome from adipose, bone marrow, placenta and Wharton's jelly. International Journal of Molecular Sciences. 2021;22(2):845. https://pubmed.ncbi.nlm.nih.gov/33467726/The single most useful citation for a sourcing conversation. Four sources profiled under matched conditions, with distinct protein signatures per source alongside shared migration and anti-apoptotic function. It supports both halves of an honest claim.
5. 5.Peer-reviewedSemenova E, Grudniak MP, Machaj EK, et al. Mesenchymal stromal cells from different parts of umbilical cord: approach to comparison and characteristics. Stem Cell Reviews and Reports. 2021;17(5):1780-1795. https://pubmed.ncbi.nlm.nih.gov/33860454/Compares zones within the cord itself. The practical consequence is that umbilical cord derived and Wharton jelly derived are not interchangeable labels, and a COA that says only umbilical cord has under-specified the starting material.
6. 6.Peer-reviewedDrobiova H, Sindhu S, Ahmad R, Haddad D, Al-Mulla F, Al Madhoun A. Wharton's jelly mesenchymal stem cells: a concise review of their secretome and prospective clinical applications. Frontiers in Cell and Developmental Biology. 2023;11:1211217. https://pubmed.ncbi.nlm.nih.gov/37440921/Current narrative review of the secretome. Good orientation for a practitioner new to the tissue, though it is a review rather than primary evidence and should be cited as such in patient-facing material.
7. 7.Peer-reviewedChopra N, Choudhury S, Bhargava S, Wajid S, Ganguly NK. Biophysical characterization and drug delivery potential of exosomes from human Wharton's jelly-derived mesenchymal stem cells. ACS Omega. 2019;4(8):13143-13152. https://pubmed.ncbi.nlm.nih.gov/31460441/Biophysical rather than biological characterization: size distribution, zeta potential, morphology. This is the class of data a Certificate of Analysis should carry, and its absence is informative.
8. 8.Peer-reviewedBuitrago JC, Cruz-Barrera M, Dorsant-Ardón V, et al. Large and small extracellular vesicles from Wharton's jelly MSCs: biophysics, function, and strategies to improve immunomodulation. Molecular Therapy Methods and Clinical Development. 2024;32(4):101353. https://pubmed.ncbi.nlm.nih.gov/39512906/Separates large from small vesicle populations and shows they behave differently. Directly relevant to any product that reports a single particle count without a size distribution behind it.
9. 9.Peer-reviewedYu HR, Huang HC, Chen IL, Li SC. Exosomes secreted by Wharton's jelly-derived mesenchymal stem cells promote the ability of cell proliferation and migration for keratinocyte. International Journal of Molecular Sciences. 2024;25(9):4758. https://pubmed.ncbi.nlm.nih.gov/38731977/In vitro keratinocyte model. Relevant to topical aesthetic context, with the standard caveat that a migration assay in culture is several inferential steps away from a clinical outcome in skin.
10. 10.Peer-reviewedZhao G, Liu F, Liu Z, et al. MSC-derived exosomes attenuate cell death through suppressing AIF nucleus translocation and enhance cutaneous wound healing. Stem Cell Research and Therapy. 2020;11(1):174. https://pubmed.ncbi.nlm.nih.gov/32393338/Mechanistic work on an apoptosis-independent cell death pathway. Cited here as an example of cargo-level mechanism rather than as evidence for any specific clinical application.
11. 11.Peer-reviewedKim J, Lee SK, Jung M, et al. Clinical-scale mesenchymal stem cell-derived extracellular vesicle therapy for wound healing. International Journal of Molecular Sciences. 2023;24(5):4273. https://pubmed.ncbi.nlm.nih.gov/36901703/Addresses the manufacturing question most supplier conversations skip: what changes when isolation moves from bench scale to clinical scale. Batch-to-batch consistency is a property of manufacturing discipline.
12. 12.Peer-reviewedWelsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. Journal of Extracellular Vesicles. 2024;13(2):e12404. https://pubmed.ncbi.nlm.nih.gov/38326288/The reporting framework the field agreed on. Any supplier characterization package should be legible against MISEV2023 categories. Our separate COA guide walks through the specific line items.
13. 13.Peer-reviewedSoder RP, Dawn B, Weiss ML, et al. A phase I study to evaluate two doses of Wharton's jelly-derived mesenchymal stromal cells for the treatment of de novo high-risk or steroid-refractory acute graft versus host disease. Stem Cell Reviews and Reports. 2020;16(5):979-991. https://pubmed.ncbi.nlm.nih.gov/32740891/A registered phase I trial of this specific tissue source under IND. Worth knowing because it marks the difference between the investigational pathway and the products marketed outside it.
14. 14.Peer-reviewedIshak-Samrin M, Kamarul T, Ng MH, et al. Treatment of knee osteoarthritis and chondral injury with umbilical cord/Wharton's jelly-derived mesenchymal stem cells: a systematic review of safety and efficacy. Journal of Functional Biomaterials. 2025;16(3):95. https://pubmed.ncbi.nlm.nih.gov/40137363/Systematic review reporting functional improvement across VAS, WOMAC, KOOS and IKDC with mixed radiological findings. The divergence between symptom scores and imaging is the honest summary of this literature.
15. 15.Peer-reviewedDhillon J, Kraeutler MJ, Belk JW, et al. Safety and efficacy of umbilical cord-derived Wharton's jelly compared to hyaluronic acid and saline for knee osteoarthritis: study protocol for a randomized, controlled, single-blind, multi-center trial. Journal of Orthopaedic Surgery and Research. 2021;16(1):356. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165766/Published protocol rather than results. Cited to show that a controlled comparison against hyaluronic acid and saline was designed, which is the comparison the observational literature lacks.
16. 16.RegulatoryUS Food and Drug Administration. Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use. Guidance for industry and FDA staff. July 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimalThe controlling guidance for whether a birth-tissue product is regulated as a 361 HCT/P or as a biologic requiring a BLA. Both criteria must be met, and the guidance addresses umbilical tissue directly.
17. 17.RegulatoryUS Food and Drug Administration. Public safety notification on exosome products. December 6, 2019. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-productsThe agency notification setting out the current federal position on exosome products, issued following adverse events reported in patients treated with unapproved preparations. The primary source for regulatory status in this category.
18. 18.RegulatoryUS Food and Drug Administration. Consumer alert on regenerative medicine products including stem cells and exosomes. July 2020. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomesThe patient-facing counterpart to the safety notification. Useful as a reference point when calibrating what a practice website may responsibly say.
19. 19.RegulatoryUS Code of Federal Regulations. Title 21, Part 1271: Human cells, tissues, and cellular and tissue-based products. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271Includes the donor eligibility, screening and testing requirements at Subpart C and the current good tissue practice requirements at Subpart D. Ask suppliers which subparts they operate under.
20. 20.StandardUnited States Pharmacopeia. General Chapter <71>, Sterility Tests. https://www.usp.org/The sterility method a release test should name. A COA reporting sterility without naming the compendial method has reported a conclusion rather than a test.
21. 21.StandardUnited States Pharmacopeia. General Chapter <85>, Bacterial Endotoxins Test. https://www.usp.org/Endotoxin limits belong on every release document for a parenteral or an injectable-adjacent preparation, expressed in EU/mL against a stated limit rather than as a pass/fail mark.
22. 22.StandardInternational Society for Extracellular Vesicles. Position and guideline resources, including the MISEV series and rigor and standardization subcommittee output. https://www.isev.org/The professional body behind MISEV. Its guidance is the reference frame a scientifically literate supplier will already be using without being asked.
23. 23.RegulatoryFlorida Senate Bill 1768 (2019), codified in Florida Statutes Chapter 381, governing stem cell therapy not approved by the FDA. https://www.flsenate.gov/Session/Bill/2019/1768Adds a Florida-specific disclosure and posting obligation on top of the federal framework. Relevant to any Florida practice offering birth-tissue derived products.
24. 24.RegulatoryUS Food and Drug Administration. Warning letters issued to manufacturers and distributors of exosome and birth-tissue products, 2019 through 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersSearchable enforcement record. Running a prospective supplier through this database is the least expensive diligence step available and is rarely performed.